Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 4/20 | 0.42 |
| ▸ | CTSL | P07711 | 2/20 | 0.42 |
| ▸ | CTSB | P07858 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11886701 | 0.91 | SYK (0.54) | SYKHTTSMN1; SMN2LMNAATM | |
| SCHEMBL28766687 | 0.91 | SYK (0.48) | SYKHTTSMN1; SMN2LMNAATM | |
| SCHEMBL30500895 | 0.88 | SYK (0.60) | SYKHTTSMN1; SMN2LMNAATM | |
| SCHEMBL18654075 | 0.83 | SYK (0.48) | SYKHTTSMN1; SMN2LMNAATM | |
| SCHEMBL11886704 | 0.82 | SYK (0.47) | SYKHTTSMN1; SMN2LMNAATM | |
| SCHEMBL1022651 | 0.81 | SYK (0.53) | SYKMAPTCTSSCTSLCTSB | |
| SCHEMBL1022650 | 0.81 | SYK (0.53) | SYKMAPTCTSSCTSLCTSB | |
| SCHEMBL6989963 | 0.79 | GRIN2D (0.47) | HTTSMN1; SMN2LMNAMAPK1 | |
| SCHEMBL12703535 | 0.79 | KMT2A (0.46) | CTSK | |
| SCHEMBL21383878 | 0.79 | HTT (0.50) | HTTSMN1; SMN2LMNAATMMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120189623-A1 | CYCLIZED DERIVATIVES AS EG-5 INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2012-07-26 | — | — | US | disclosed |
| US-20120189623-A1 | CYCLIZED DERIVATIVES AS EG-5 INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2012-07-26 | — | — | US | disclosed |
| US-20110003791-A1 | Cyclized Derivatives as EG-5 Inhibitors | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2011-01-06 | — | — | US | disclosed |
| US-20110003791-A1 | Cyclized Derivatives as EG-5 Inhibitors | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2011-01-06 | — | — | US | disclosed |
| US-7820646-B2 | Cyclized derivatives as Eg-5 inhibitors | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-7820646-B2 | Cyclized derivatives as Eg-5 inhibitors | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-10-26 | — | — | US | disclosed |
| EP-2106399-A2 | IMIDAZOLE DERIVATIVES AS KINESIN SPINDLE PROTEIN INHIBITORS (EG-5) | Novartis AG (CH) | 2009-10-07 | — | — | EP | disclosed |
| US-20080207589-A1 | CYCLIZED DERIVATIVES AS EG-5 INHIBITORS | NOVARTIS AG | 2008-08-28 | — | — | US | disclosed |
| US-20080207589-A1 | CYCLIZED DERIVATIVES AS EG-5 INHIBITORS | NOVARTIS AG | 2008-08-28 | — | — | US | disclosed |
| WO-2008086122-A2 | IMIDAZOLE DERIVATIVES AS KINESIN SPINDLE PROTEIN INHIBITORS (EG-5) | NOVARTIS AG (CH) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003791-A1 | Cyclized Derivatives as EG-5 Inhibitors | CYP3A5, GDI2, HDAC5 | SYK 4132/4885HTT 1665/4885SMN1; SMN2 4796/4885 |
| US-20120189623-A1 | CYCLIZED DERIVATIVES AS EG-5 INHIBITORS | CYP3A5, GDI2, HDAC5 | SYK 4132/4885HTT 1665/4885SMN1; SMN2 4796/4885 |
| US-20080207589-A1 | CYCLIZED DERIVATIVES AS EG-5 INHIBITORS | CYP3A5, GDI2, HDAC5 | SYK 4132/4885HTT 1665/4885SMN1; SMN2 4796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.